Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9873388rdf:typepubmed:Citationlld:pubmed
pubmed-article:9873388lifeskim:mentionsumls-concept:C0058698lld:lifeskim
pubmed-article:9873388lifeskim:mentionsumls-concept:C0028027lld:lifeskim
pubmed-article:9873388lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:9873388lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:9873388lifeskim:mentionsumls-concept:C1510827lld:lifeskim
pubmed-article:9873388pubmed:issue12lld:pubmed
pubmed-article:9873388pubmed:dateCreated1999-2-1lld:pubmed
pubmed-article:9873388pubmed:abstractTextA series of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamide derivatives were prepared and evaluated for their binding to 5-HT3 and dopamine D2 receptors. Among them, the 5-bromo-2-methoxy-6-methylaminonicotinamide 16 and its (R)-isomer were found to have potent affinities for both receptors. The affinities of (R)-16 for 5-HT3 and dopamine D2 receptors are approximately 3-fold higher than those of the corresponding benzamide (R)-1 (IC50: 1.1 and 12 nM vs. 2.9 and 35 nM, respectively).lld:pubmed
pubmed-article:9873388pubmed:languageenglld:pubmed
pubmed-article:9873388pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873388pubmed:citationSubsetIMlld:pubmed
pubmed-article:9873388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873388pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9873388pubmed:statusMEDLINElld:pubmed
pubmed-article:9873388pubmed:monthJunlld:pubmed
pubmed-article:9873388pubmed:issn0960-894Xlld:pubmed
pubmed-article:9873388pubmed:authorpubmed-author:KatoSSlld:pubmed
pubmed-article:9873388pubmed:authorpubmed-author:YoshidaNNlld:pubmed
pubmed-article:9873388pubmed:authorpubmed-author:HirokawaYYlld:pubmed
pubmed-article:9873388pubmed:issnTypePrintlld:pubmed
pubmed-article:9873388pubmed:day16lld:pubmed
pubmed-article:9873388pubmed:volume8lld:pubmed
pubmed-article:9873388pubmed:ownerNLMlld:pubmed
pubmed-article:9873388pubmed:authorsCompleteYlld:pubmed
pubmed-article:9873388pubmed:pagination1551-4lld:pubmed
pubmed-article:9873388pubmed:dateRevised2003-11-14lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:meshHeadingpubmed-meshheading:9873388-...lld:pubmed
pubmed-article:9873388pubmed:year1998lld:pubmed
pubmed-article:9873388pubmed:articleTitleSynthesis of N-(1-ethyl-4-methylhexahydro-1,4-diazepin-6-yl)nicotinamides and their affinities for 5-HT3 and dopamine D2 receptors.lld:pubmed
pubmed-article:9873388pubmed:affiliationDiscovery Research Laboratory I, Dainippon Pharmaceutical Co., Ltd., Osaka, Japan.lld:pubmed
pubmed-article:9873388pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...http://linkedlifedata.com/r...pubmed-article:9873388lld:chembl